[go: up one dir, main page]

CA2113494A1 - Methode de dosage de substances affectant la transformation mediee par bcr-abl - Google Patents

Methode de dosage de substances affectant la transformation mediee par bcr-abl

Info

Publication number
CA2113494A1
CA2113494A1 CA 2113494 CA2113494A CA2113494A1 CA 2113494 A1 CA2113494 A1 CA 2113494A1 CA 2113494 CA2113494 CA 2113494 CA 2113494 A CA2113494 A CA 2113494A CA 2113494 A1 CA2113494 A1 CA 2113494A1
Authority
CA
Canada
Prior art keywords
grb2
leu
bcr
pro
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2113494
Other languages
English (en)
Inventor
Lorri Puil
Anthony Pawson
Ralph Arlinghaus
Gerald Gish
Jiaxin Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mt Sinai Hospital
University of Texas at Austin
Original Assignee
Mt Sinai Hospital
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mt Sinai Hospital, University of Texas at Austin filed Critical Mt Sinai Hospital
Priority to CA 2113494 priority Critical patent/CA2113494A1/fr
Publication of CA2113494A1 publication Critical patent/CA2113494A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA 2113494 1994-01-14 1994-01-14 Methode de dosage de substances affectant la transformation mediee par bcr-abl Abandoned CA2113494A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2113494 CA2113494A1 (fr) 1994-01-14 1994-01-14 Methode de dosage de substances affectant la transformation mediee par bcr-abl

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2113494 CA2113494A1 (fr) 1994-01-14 1994-01-14 Methode de dosage de substances affectant la transformation mediee par bcr-abl

Publications (1)

Publication Number Publication Date
CA2113494A1 true CA2113494A1 (fr) 1995-07-15

Family

ID=4152741

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2113494 Abandoned CA2113494A1 (fr) 1994-01-14 1994-01-14 Methode de dosage de substances affectant la transformation mediee par bcr-abl

Country Status (1)

Country Link
CA (1) CA2113494A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721586A4 (fr) * 1993-09-28 1996-09-25 Univ New York Med Ct Procedes et compositions de traitement des leucemies associees a bcr-abl et d'autres affections a proliferations cellulaires
WO1998001547A1 (fr) * 1996-07-08 1998-01-15 The Board Of Regents, The University Of Texas System INHIBITION DE LA PROLIFERATION DES CELLULES DE LEUCEMIE MYELOIDE CHRONIQUE (LMC) PAR CIBLAGE SUR Grb2 OU Crk1 D'OLIGODESOXYNUCLEOTIDES LIPOSOMIQUES-ANTISENS CORRESPONDANT
EP0811078A4 (fr) * 1995-02-16 2000-01-26 Univ Texas Compositions dirigees contre bcr-abl et leurs utilisations pour inhiber la croissance cellulaire stimulee par le chromosome de philadelphie

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721586A4 (fr) * 1993-09-28 1996-09-25 Univ New York Med Ct Procedes et compositions de traitement des leucemies associees a bcr-abl et d'autres affections a proliferations cellulaires
US6066463A (en) * 1993-09-28 2000-05-23 New York University Method and compositions for treatment of BCR-ABL associated leukemias and other cell proliferative disorders
US6528270B1 (en) 1993-09-28 2003-03-04 Sugen, Inc. Methods for identifying compounds for treatment of cell proliferative disorders associated with adaptor protein interactions
EP0811078A4 (fr) * 1995-02-16 2000-01-26 Univ Texas Compositions dirigees contre bcr-abl et leurs utilisations pour inhiber la croissance cellulaire stimulee par le chromosome de philadelphie
WO1998001547A1 (fr) * 1996-07-08 1998-01-15 The Board Of Regents, The University Of Texas System INHIBITION DE LA PROLIFERATION DES CELLULES DE LEUCEMIE MYELOIDE CHRONIQUE (LMC) PAR CIBLAGE SUR Grb2 OU Crk1 D'OLIGODESOXYNUCLEOTIDES LIPOSOMIQUES-ANTISENS CORRESPONDANT
AU740289B2 (en) * 1996-07-08 2001-11-01 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to Grb2 or Crk1
US7220853B2 (en) 1996-07-08 2007-05-22 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to Grb2 or Crk1
US7309692B1 (en) 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US7923548B2 (en) 1996-07-08 2011-04-12 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to Grb2 or Crk1

Similar Documents

Publication Publication Date Title
Puil et al. Bcr‐Abl oncoproteins bind directly to activators of the Ras signalling pathway.
Kashishian et al. Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase in vivo.
JP3561268B2 (ja) レセプターチロシンキナーゼ標的タンパク質のcDNAクローニング方法及びhGRBタンパク質
US6037134A (en) Methods that detect compounds that disrupt receptor tyrosine kinase/GRB-7 complexes
US5736337A (en) Inhibiting protein interactions
EP2881402B1 (fr) Expression de la protéine mutante ROS dans les cancers du foie chez l'être humain
JP5554925B2 (ja) ヒト非小細胞肺癌における転座及び変異体rosキナーゼ
Martinu et al. Endocytosis of epidermal growth factor receptor regulated by Grb2-mediated recruitment of the Rab5 GTPase-activating protein RN-tre
Bai et al. The SH2-containing adapter protein GRB10 interacts with BCR-ABL
US5667981A (en) Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein
CA2250702A1 (fr) Domaines a activite de survie du recepteur du facteur i de croissance de type insulinique (igf-ir) et techniques d'utilisation
AU735287C (en) Compounds that inhibit interaction between signal-transducing proteins and the GLGF (PDZ/DHR) domain and uses thereof
Wolf et al. Fiz1, a novel zinc finger protein interacting with the receptor tyrosine kinase Flt3
US5955259A (en) Method for assessing modulation of potassium ion channel activity
US6045797A (en) Treatment or diagnosis of diseases or conditions associated with a BLM domain
US6255074B1 (en) Abl-interactor protein
CA2113494A1 (fr) Methode de dosage de substances affectant la transformation mediee par bcr-abl
EP0797662B1 (fr) Methodes de traitement ou de diagnostic de maladies ou d'etats associes a une transduction anormale des signaux
US5667980A (en) Method for assaying for a substance that affects an SH2 phosphorylated ligand regulatory system
WO2012075318A2 (fr) Translocations des gènes fn1 et alk dans des cas de cancer et expression de l'alk kinase dans des cas de cancer de l'ovaire
HK1210482B (en) Mutant ros expression in human liver cancer

Legal Events

Date Code Title Description
FZDE Dead